Introduction Pharmacotherapeutic options continue to expand for the treatment of chronic
non-cancer pain. There has been an increasing emphasis on multimodal analgesia. This …

Migraine is a leading cause of disability worldwide. Despite the recent approval of several
calcitonin gene-related peptide-targeted therapies, many people with migraine do not …

Calcitonin-gene-related peptide (CGRP) plays a key role in migraine pathophysiology and
more specifically in the mechanisms underlying peripheral and central sensitization. Here …

Background In the absence of head-to-head trials, comprehensive evidence comparing
onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed …

Background This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg—
an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and …

Atogepant is a new drug developed for treating migraine in adults, marking it active with a
calcitonin gene-related peptide (CGRP) receptor antagonist, which can be used to prevent …

The Clinical Trials Subcommittee of the International Headache Society presents the first
Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention …

Objective The objective of this study was to characterize the utility of calcitonin gene–related
peptide (CGRP) and nerve growth factor (NGF) as potential biomarkers for headache and …

Background Vasoactive peptides play an important role in a wide range of physiological and
pathological conditions. Due to its known functions, the calcitonin gene-related peptide …

Introduction Migraine is a common debilitating neurological disorder affecting a large
proportion of the general population. Calcitonin gene-related peptide (CGRP), a 37-amino …